FORT MYERS, Fla. / May 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology testing services, today announced that it has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes with a maturity date of May 1, 2025, using cash on hand.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
| Last Trade: | US$10.45 |
| Daily Change: | 0.11 1.06 |
| Daily Volume: | 4,376,531 |
| Market Cap: | US$1.350B |
October 14, 2025 July 30, 2025 July 29, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
